• SHARE

A health ministry panel has delayed giving a stamp of approval to Shionogi’s COVID-19 anti-viral pill, concluding that it needs more data before making a judgment on its efficacy.

The delay is a blow to one of Japan’s largest drugmakers and also raises questions about the process for drugs to gain fast-track approvals in times of emergency.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)